Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis

Immune checkpoint inhibitor (ICI)-induced pneumonitis has been considered a rare immune-related adverse event (irAE). Incidence is estimated at less than 5% of clinical trial patients, with high-grade pneumonitis occurring in less than 1% of patients who receive ICIs.1 21 However, as ICIs gain